|Day Low/High||19.80 / 20.41|
|52 Wk Low/High||13.42 / 25.31|
Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") has launched MINNEBRO ® (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
Jim Cramer says that sometimes it takes a really bad day to reveal the true winning stocks.
Jim Cramer weighs in on Cisco Systems, Sunrun, Zebra Technologies, EQT Midstream Partners, Exelixis, The Trade Deck and more.
Exelixis, Inc. (NASDAQ: EXEL) today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with nivolumab (Opdivo®) and ipilimumab (Yervoy®) versus nivolumab and ipilimumab in patients with...
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Exelixis, Inc. (Nasdaq: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of cabozantinib in Japan, has applied to the Japanese Ministry of Health, Labor...
Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2019 financial results will be released on Wednesday, May 1, 2019 after the markets close.
Exelixis, Inc. (NASDAQ: EXEL) today announced that Christopher J.
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Exelixis, Inc. (NASDAQ: EXEL) today announced that the company will be presenting at the following investor conferences in March: Cowen & Co.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.
Jim Cramer takes a closer look at Fitbit, Moderna, Tilray, Exelixis, Maxar Technology, International Paper and more.
The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.
Investors are already more focused on what lies ahead when Q1 results start in early April.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Exelixis, Inc. (Nasdaq: EXEL) today announced it is initiating phase 1 clinical development for XL092, the first internally-discovered Exelixis compound to enter the clinic following the company's reinitiation of drug discovery activities.
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2018 financial results will be released on Tuesday, February 12, 2019 after the markets close.
We may be so worried about the state of the global economy that we're missing some great opportunities, Jim Cramer says.
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINNEBRO™ 1.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DNR, EXEL, GIL, HF, ITGR, TEF Downgrades: CERC, FSB, PED, QTNA Initiations: URGN Read on to get TheStreet Quant Ratings' detailed report:
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.